Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...